PRZOOM - /newswire/ -
Middletown, PA, United States, 2018/09/20 - MacuLogix, Inc., is launching the AdaptDx® in Europe during Euretina in Vienna. The AdaptDx is the first commercially available dark adaptometer that can be used in clinical practice to detect AMD at a subclinical stage - MacuLogix.com.
MacuLogix, Inc., the only company to equip eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with age-related macular degeneration (AMD), will launch the AdaptDx® in Europe during its debut at the European Society of Retina Specialists (EURETINA) annual congress in Vienna, Austria, September 20-23.
The AdaptDx is the first commercially available dark adaptometer that can be used in clinical practice to detect AMD at a subclinical stage, before structural changes in the retina like drusen become visible. As part of the introduction to its technology at EURETINA, MacuLogix® will be hosting a series of “Meet the Expert” sessions at booth C623, where renowned ophthalmologists including David Gaucher, MD (France), Robin Hamilton, MD (United Kingdom), Michael Larsen, MD (Denmark), Anat Lowenstein, MD (Israel), and Jordi Mones, MD PhD (Spain) will discuss their experience diagnosing subclinical AMD and monitoring disease progression using AdaptDx.
“Introducing the AdaptDx to the European eyecare community during EURETINA is a major milestone for our company,” said William McPhee, president and CEO of MacuLogix. “Our technology and support can enable earlier diagnosis of age-related macular degeneration, when intervention and treatment are most effective. Not only can the routine use of the AdaptDx help prevent blindness caused by AMD, we also believe it has the potential to relieve the societal costs associated with preventable vision loss in an aging population.”
AMD has been identified as the leading cause of adult blindness in developed countries because diagnosing AMD at the earliest stages has been a challenge. Patients are often asymptomatic, have good corrected visual acuity, and their retina appears normal upon clinical evaluation. Thankfully, research has shown that functional assessment of dark adaptation using the AdaptDx can radically improve diagnostic sensitivity and specificity by detecting the disease with 90% accuracy at least three years before drusen are visible, enabling clinicians to intervene before irreversible vision loss occurs.
Learn more about the AdaptDx at a “Meet the Expert” session. Contact communications[.]medeuronet.com or visit MacuLogix at EURETINA, booth C623.
MacuLogix, Inc. (maculogix.com) equips eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with AMD. By leveraging the science of dark adaptation through its AdaptDx®, MacuLogix is working to eliminate preventable blindness caused by AMD, a chronic, progressive disease that impacts over 170 million people worldwide and goes undiagnosed in 25 percent of patients. Through its AdaptDx® dark adaptation biomarker, MacuLogix enables eye care professionals to detect, monitor and treat AMD three years before it can be seen clinically. MacuLogix provides in-practice training and treatment best practices to support the implementation and optimization of the AdaptDx®.